BACKGROUND: Prehypertension (blood pressure [BP] 120-139/80-89 mm Hg) is an independent risk factor for hypertension and cardiovascular disease. Currently, it is unknown whether endothelin (ET)-1-mediated vasoconstrictor tone is elevated with BP in the prehypertensive range. The aims of this study were to determine whether ET-1 vasoconstrictor tone is elevated in prehypertensive adults and, if so, whether ET-1-mediated vasoconstriction contributes to endothelial vasodilator dysfunction in this population. METHODS: Forearm blood flow responses to selective ET(A) receptor blockade (BQ-123; 100 nmol/min) were determined in 26 normotensive adults (age 55 ± 1 years; BP 112 ± 1/72 ± 1 mm Hg) and 30 prehypertensive adults (57 ± 1 years; BP 130 ± 1/80 ± 1 mm Hg). In a subset of participants, forearm blood flow responses to nonselective ET-1 receptor blockade (BQ-123 + BQ-788) were determined. Endothelium-dependent vasodilation to acetylcholine (8.0-32.0 μg/100 mL tissue/min) was measured in the absence and presence of selective ET(A) receptor blockade. RESULTS: BQ-123 elicited a significantly greater increase in forearm blood flow in prehypertensive (approximately 20%) than in normotensive (approximately 5%) adults. Addition of BQ-788 resulted in a further increase (P < 0.05) in forearm blood flow in prehypertensive but not in normotensive adults. Forearm blood flow responses to acetylcholine were lower (P < 0.05) in prehypertensive (4.6 ± 0.3 to 12.6 ± 0.5 mL/100 mL tissue/min) than in normotensive (4.9 ± 0.3 to 14.7 ± 0.8 mL/100 mL tissue/min) adults. Co-infusion of BQ-123 did not affect acetylcholine-induced vasodilation in normotensive adults but resulted in an approximately 20% increase (P < 0.05) in prehypertensive adults. CONCLUSIONS: ET-1-mediated vasoconstrictor tone is elevated with prehypertension, contributing to impaired endothelium-dependent vasodilation. ET-1 vasoconstriction may underlie the increased risk of hypertension and cardiovascular disease in prehypertensive adults.
BACKGROUND:Prehypertension (blood pressure [BP] 120-139/80-89 mm Hg) is an independent risk factor for hypertension and cardiovascular disease. Currently, it is unknown whether endothelin (ET)-1-mediated vasoconstrictor tone is elevated with BP in the prehypertensive range. The aims of this study were to determine whether ET-1 vasoconstrictor tone is elevated in prehypertensive adults and, if so, whether ET-1-mediated vasoconstriction contributes to endothelial vasodilator dysfunction in this population. METHODS: Forearm blood flow responses to selective ET(A) receptor blockade (BQ-123; 100 nmol/min) were determined in 26 normotensive adults (age 55 ± 1 years; BP 112 ± 1/72 ± 1 mm Hg) and 30 prehypertensive adults (57 ± 1 years; BP 130 ± 1/80 ± 1 mm Hg). In a subset of participants, forearm blood flow responses to nonselective ET-1 receptor blockade (BQ-123 + BQ-788) were determined. Endothelium-dependent vasodilation to acetylcholine (8.0-32.0 μg/100 mL tissue/min) was measured in the absence and presence of selective ET(A) receptor blockade. RESULTS:BQ-123 elicited a significantly greater increase in forearm blood flow in prehypertensive (approximately 20%) than in normotensive (approximately 5%) adults. Addition of BQ-788 resulted in a further increase (P < 0.05) in forearm blood flow in prehypertensive but not in normotensive adults. Forearm blood flow responses to acetylcholine were lower (P < 0.05) in prehypertensive (4.6 ± 0.3 to 12.6 ± 0.5 mL/100 mL tissue/min) than in normotensive (4.9 ± 0.3 to 14.7 ± 0.8 mL/100 mL tissue/min) adults. Co-infusion of BQ-123 did not affect acetylcholine-induced vasodilation in normotensive adults but resulted in an approximately 20% increase (P < 0.05) in prehypertensive adults. CONCLUSIONS: ET-1-mediated vasoconstrictor tone is elevated with prehypertension, contributing to impaired endothelium-dependent vasodilation. ET-1 vasoconstriction may underlie the increased risk of hypertension and cardiovascular disease in prehypertensive adults.
Authors: Zachary I Grunewald; Thomas J Jurrissen; Makenzie L Woodford; Francisco I Ramirez-Perez; Lauren K Park; Ryan Pettit-Mee; Thaysa Ghiarone; Scott M Brown; Mariana Morales-Quinones; James R Ball; Kevin F Staveley-O'Carroll; Annayya R Aroor; Paul J Fadel; Pierre Paradis; Ernesto L Schiffrin; Shawn B Bender; Luis A Martinez-Lemus; Jaume Padilla Journal: Hypertension Date: 2019-10-21 Impact factor: 10.190
Authors: Benjamin E Young; Jaume Padilla; Stine H Finsen; Paul J Fadel; Stefan P Mortensen Journal: Endocrinology Date: 2022-03-01 Impact factor: 4.736
Authors: John D Akins; Rauchelle E Richey; Jeremiah C Campbell; Zachary T Martin; Guillermo Olvera; R Matthew Brothers Journal: Am J Physiol Heart Circ Physiol Date: 2021-12-17 Impact factor: 4.733
Authors: C E Storniolo; R Casillas; M Bulló; O Castañer; E Ros; G T Sáez; E Toledo; R Estruch; V Ruiz-Gutiérrez; M Fitó; M A Martínez-González; J Salas-Salvadó; M T Mitjavila; J J Moreno Journal: Eur J Nutr Date: 2015-10-08 Impact factor: 5.614
Authors: Kyle J Diehl; Brian L Stauffer; Caitlin A Dow; Tyler D Bammert; Danielle L Brunjes; Jared J Greiner; Christopher A DeSouza Journal: Hypertension Date: 2016-04-25 Impact factor: 10.190